Wet AMD, Therapy Development

Daniel F. Martin, MD

Cole Eye Institute, Cleveland Clinic  

Daniel F. Martin MD is Chair of the Cleveland Clinic Cole Eye Institute, the Barbara and A. Malachi Mixon III Institute Chair in Ophthalmology, and Professor of Ophthalmology in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.  Dr. Martin’s primary research interest is in clinical trials and the evaluation of new treatments for AMD.  Dr. Martin treated the first person in the world with an anti-VEGF drug and led some of the earliest studies evaluating new drugs for neovascular AMD.  In addition, Dr. Martin served as a principal investigator for dry AMD trials, such as AREDS I and AREDS II.  From 2005-2017, Dr Martin served as the Study Chair for the Comparison of AMD Treatments Trials (CATT) and the CATT Follow-Up Study.  Currently, Dr Martin serves as the Network Chair for the DRCR Retina Network, which has recently expanded its scope to include evaluation of new treatments for all retinal diseases.  Within the DRCR Retina Network, Dr Martin has primary responsibility for all AMD and other non-diabetic retinopathy trials.